Addus HomeCare Corporation (ADUS) — Fair Value Analysis

Base-case fair value (P50): $97.18 · Current price: $90.98 · Verdict: Fairly Valued

The Verdict on ADUS

ADDUS HOMECARE CORP (ADUS) currently trades at $90.98, indicating it is Fairly Valued based on our latest Monte Carlo simulations. Our quantitative analysis, modeling thousands of potential future scenarios for ADUS, indicates a median fair value (P50) of $97.18. This target suggests a potential +6.8% from ADUS's current trading level. While the share price sits below our P50 fair value, the implied upside is not substantial enough to categorize ADUS as undervalued, instead pointing towards a balanced risk-reward profile. This assessment integrates ADUS's operational and financial health against its broader Healthcare sector context.

How ADUS stacks up against Healthcare

Within the competitive Healthcare sector, ADUS's operational and financial health is currently deemed average. This quality tier is a critical input in our Monte Carlo simulations, directly influencing the probabilistic range and distribution of ADUS's fair value outcomes. Despite this average fundamental quality, the simulation’s median output of $97.18 still provides a moderate +6.8% buffer compared to the present $90.98. This suggests that even with average fundamentals, the market pricing of $90.98 is largely in line with its underlying value, supporting the Fairly Valued verdict. The average quality tier reinforces ADUS is priced appropriately for its standing within the sector.

What this means for investors

For investors evaluating ADDUS HOMECARE CORP, the current trading price of $90.98 relative to our median fair value (P50) of $97.18 firmly lands the stock in the Fairly Valued category. The +6.8% implied by our P50 target suggests significant immediate mispricing is unlikely based on our quantitative models. Furthermore, an average quality tier reinforces this balanced perspective, indicating that while ADUS demonstrates stability, it may not present extraordinary operational outperformance compared to higher-tier companies within the Healthcare sector. Investors seeking deeper insights into ADUS's potential downside or more optimistic bull-case scenarios are encouraged to sign up for a free FairCurve account to access the full Monte Carlo distribution and track ADUS's dynamic fair value as new financial data is released.